Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma

Immune checkpoint blockade (ICB) therapy is a treatment strategy for hepatocellular carcinoma (HCC); however, its clinical efficacy is limited to a select subset of patients. Next-generation sequencing has identified the value of tumor mutation burden (TMB) as a predictor for ICB efficacy in multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Rao, Xiaosong, Wen, Zhaohong, Ding, Xiaosheng, Wang, Xiangyi, Xu, Weiran, Meng, Chao, Yi, Yuting, Guan, Yanfang, Chen, Yongshen, Wang, Jiayin, Jun, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068659/
https://www.ncbi.nlm.nih.gov/pubmed/32218826
http://dx.doi.org/10.3892/ol.2020.11372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068659/
https://www.ncbi.nlm.nih.gov/pubmed/32218826
http://dx.doi.org/10.3892/ol.2020.11372

Ejemplares similares